Marché mondial des services de tests bioanalytiques – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse du marché et de la taille des services de tests bioanalytiques

Les dispositifs de test bioanalytique sont utilisés pour ordonner les métabolites et les médicaments présents dans les mesures biologiques. Par exemple, les fluides, le sang primaire, le plasma, les extraits de tissus, le sérum ou l'urine. Il s'agit également d'une méthode analytique pour analyser les produits biologiques. Les opérations d'un programme bioanalytique comprennent la préparation des échantillons, le développement de techniques bioanalytiques, la validation et la garantie de résultats quantitatifs avec exactitude, sélectivité, précision et stabilité. La préparation de l'échantillon comprend le nettoyage de l'échantillon d'essai avant de commencer l'analyse et la concentration de l'échantillon pour une meilleure détection.

Français Data Bridge Market Research analyse que le marché des services de tests bioanalytiques, qui était de 3,64 milliards USD en 2021, devrait atteindre 9,88 milliards USD d'ici 2029, à un TCAC de 13,30 % au cours de la période de prévision 2022 à 2029. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des services de tests bioanalytiques      

Définition du marché

Les services de tests bioanalytiques sont utilisés pour quantifier les concentrations de médicaments, les métabolites et les biomarqueurs pharmacodynamiques dans les fluides biologiques. Ces services comprennent la validation des méthodes pour garantir des résultats qui démontrent l'exactitude, la précision, la sélectivité et la stabilité ainsi que des résultats d'analyse d'échantillons précis.

Dynamique du marché mondial des services de tests bioanalytiques

Conducteurs

• Augmentation du nombre de services d'externalisation de laboratoire

L'externalisation des services bioanalytiques devient de plus en plus populaire afin de maximiser l'utilisation des ressources. Bien que les laboratoires internes dédiés disposent d'équipements de pointe, ils peuvent être incapables de gérer des tests bioanalytiques complexes. De plus, sur le plan stratégique, la gestion de laboratoires internes peut être coûteuse. L'externalisation du rôle de laboratoire réduit les frais généraux et opérationnels, permettant aux entreprises de continuer à bénéficier de ces services de laboratoire. L'externalisation des laboratoires aide les entreprises et autres institutions à gagner de l'argent en leur permettant d'échanger des coûts fixes plus élevés contre des coûts variables plus bas, réduisant ainsi le besoin d'investissement en capital dans l'entreprise et offrant un accès instantané à une expertise et à des capacités analytiques de classe mondiale dans un court délai. Les facteurs mentionnés ci-dessus stimulent considérablement la croissance du marché.

• Hausse des dépenses de R&D dans l'industrie pharmaceutique et biopharmaceutique

The pharmaceutical industry spent a total of 136 billion dollars in 2012. In 2019, it spent 186 billion dollars on research and development. According to PhRMA, research and development (R&D) investment by PhRMA member companies totaled 83 billion US dollars in 2019, making the biopharmaceutical industry the most R&D-intensive industry in the US economy. In fact, the biopharmaceutical industry invests six times as much in research and development as all other manufacturing sectors combined. Over the last few decades, PhRMA member companies have invested nearly USD 1 trillion in the discovery and development of new and improved drugs and cures. Usually during the pre-clinical phase, the regulatory authority is involved in the process to oversee, control, and eventually authorise the drugs. Major advances in pharmaceutical research and development have begun to alter the R&D landscape in recent years.

Opportunities

• Rising demand of biosimilar

The increased expiration of patents has resulted in the emergence of biosimilar. Even though biosimilar are similar to their original drug in chemical composition and other aspects, these drugs must go through several stages of drug development to prove their safety and efficacy. The number of biosimilar in the pipeline has increased by more than 200% since 2013; there are now more than 1,050 biosimilar in various stages of development.

Restraints/Challenges

• Lack of dearth of skilled professionals

There is an increase in demand worldwide for qualified healthcare professionals. Approximately 80 million healthcare workers would be required worldwide by 2030, according to an estimate that was published in the journal Human Resources for Health in 2016. However, it is anticipated that only 65 million healthcare professionals will be available by 2020, leaving a 15 million global shortage. Despite the fact that there should be 23 qualified professionals for every 10,000 people, 83 nations still fall short of the goal. In 2012, 6.6 million children under the age of five lost their lives. Diseases that could have been prevented or cured were to blame for the majority of fatalities.

This bioanalytical testing services market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bioanalytical testing services market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Bioanalytical Testing Services Market

The COVID-19 pandemic had a significant impact on the global economy, as well as business operations. The high infection rates and negative impact on public health systems, several countries were forced to implement nationwide lockdowns, which had a significant impact on industrial supply chains, trade, and related services. COVID-19 also caused a drop in the market for global bioanalytical testing services. Furthermore, limited clinic access, combined with social distancing norms and complete lockdown declared by several countries, resulted in a slowdown in patient flow and referral, affecting market growth. Cancer screenings dropped dramatically during the COVID-19 epidemic. Cervical cancer screenings decreased by 68% in the first 15 weeks of 2020 in the United States, while breast cancer screenings increased.

COVID-19 pandemic has presented the bioanalytical community with new challenges. One year later, the pandemic's impact on business practises, supply chains, timelines, and project prioritisation is still being felt throughout the industry. Laboratories have modified their day-to-day lab operations and clinical trial procedures because of travel and personnel constraints. Supply chains have been disrupted, resulting in decreased availability of lab consumables, reagents, personal protective equipment (PPE), and biological matrices. COVID-19 clinical trials have more diverse analytical needs than traditional therapeutic candidates, as each therapeutic may require pharmacokinetic, immunogenicity, biomarker, SARS-CoV-2 antigen, and serological testing.

Recent Developments

• In January 2021, Eurofin's bioanalytical services division announced the launch of a surrogate virus neutralisation antibody assay against the COVID-19 virus. This is the first neutralising antibody serology test for SARS-CoV-2 virus that has been approved by the FDA as an Emergency Use Authorization (EUA). As a result of such innovative initiatives, the market is expected to grow significantly by 2020. The market is also expected to grow profitably over the forecast period, owing to a significant increase in demand for such services following the pandemic.
• On February 17, 2021, Charles River Laboratories announced the acquisition of Cognate BioServices, a leading cell and gene therapy contract development and manufacturing organisation (CDMO), and Cobra Biologics, its gene therapy division. Charles River will be established as a leading scientific partner for cell and gene therapy development, testing, and manufacturing, providing clients with an integrated solution from early research and discovery to CGMP production.

Global Bioanalytical Testing Services Market Scope

The bioanalytical testing services market is segmented on the basis of test type, molecule type, type, application, workflow and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

• ADME
• In-Vivo
• In-Vitro
• Pharmacokinetic Test
• Pharmacodynamic Test
• Bioequivalence Test
• Bioavailability Test
• Other Test

 Molecule Type

• Small Molecule
• Large Molecule
• LC-MS Studies
• Immunoassays
• PK
• ADA
• Others
• Others

 Type

• Cell-Based Assays
• Virology Testing
• Method Development Optimization and Validation
• Serology
• Immunogenicity
• Neutralizing Antibodies
• Biomarker Testing
• Pharmacokinetic Testing
• Others

 Application

• Oncology
• Neurology
• Infectious Diseases
• Gastroenterology
• Cardiology
• Other Applications

Workflow

• Sample Preparation
• Protein Precipitation
• Liquid-Liquid Extraction
• Solid Phase Extraction
• Sample Analysis
• Hyphenated technique
• Chromatographic technique
• Electrophoresis
• Ligand Binding Assay
• Mass Spectrometry
• Nuclear Magnetic Resonance
• Other Work Flow Processes

 End User

• Pharmaceutical
• Biopharmaceutical Companies
• Contract Development
• Manufacturing Organizations
• Contract Research Organizations

Bioanalytical Testing Services Market Regional Analysis/Insights

The bioanalytical testing services market is analysed and market size insights and trends are provided by country, test type, molecule type, type, application, workflow and end user as referenced above.

The countries covered in the bioanalytical testing services market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the bioanalytical testing services market due to increasing demand for bioanalytical services, which is likely to drive market expansion in the region due to the volume of active research projects and clinical trials.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to rise in the number of businesses using services, rise in investments by organizations providing bioanalytical testing services in the region, corporate and regulatory reforms.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché des services de tests bioanalytiques

Le paysage concurrentiel du marché des services de tests bioanalytiques fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché des services de tests bioanalytiques.

Certains des principaux acteurs opérant sur le marché des services de tests bioanalytiques sont :

• Charles River Laboratories (États-Unis)
• Medpace (États-Unis)
• WuXi AppTec (Chine)
• Eurofins Scientifique (Luxembourg)
• IQVIA (États-Unis)
• SGS Société Générale de Surveillance SA (Suisse)
• Intertek Group plc (Royaume-Uni)
• Syneos Health. (Royaume-Uni)
• ICON plc (Irlande)
• PPD Inc. (États-Unis)
• Parexel International Corporation. (États-Unis)
• Groupe Almac (Royaume-Uni)
• Altasciences. (Canada)
• Laboratoires BioAgilytix. (États-Unis)
• LGC Limited (Royaume-Uni)

SKU-55667